Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short-term Investments Total Current Liabilities Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

CorMedix (CRMD) Receivables - Other (2024 - 2025)

CorMedix has reported Receivables - Other over the past 4 years, most recently at $4.0 million for Q3 2025.

Quarterly results put Receivables - Other at $4.0 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $4.0 million (changed N/A YoY), and the annual figure for FY2011 was $493855.0, up 75.8%.
Receivables - Other reached $4.0 million in Q3 2025 per CRMD's latest filing, up from $500000.0 in the prior quarter.
Across five years, Receivables - Other topped out at $4.0 million in Q3 2025 and bottomed at $500000.0 in Q2 2024.